LoginSubscribe Now
International In-house Counsel Journal Logo
International In-house Counsel Journal Logo
  • Home
  • Business Sectors
  • Areas of Law
  • Editorial Board
  • Write a Paper
  • Subscribe
  • Books
  • Reports
  • Back Issues
  • Terms and Conditions
  • Cookie Policy
  • Privacy Policy
  • PLS LogoCopyright & permissions
© 2026 International In-house Counsel Journal Ltd. | ISSN 1754-0607 | Picture Credits: Freepix, Unsplash and by permission of the authors
Back to library search

Pharmaceutical Patent Protection in Turkey

June 2011Intellectual PropertyPharmaceutical

Abstract

Between 1994 and 1995, Turkey conducted necessary legislative studies to establish an efficient and contemporary industrial property system and obtained very important concrete results. Turkey has ratified many international agreements regarding the IP system and as a result of this, pharmaceutical products and their process procedures have also started to be protected by Intellectual Property (IP) rights since 1st January 1999. This means an important Turkish Industrial Property Revolution. The international agreements regarding the IP system are, PCT (Patent Cooperation Treaty) which has come into force in 1st January 1996 and the EPC (European Patent Convention) in 1st November 2000. As a result of these changes, Turkey has some problems as other developing countries during the transition periods concerning their IP system.

Subscribe to reador
PLS Logo Copyright & permissions

Author

Gaye Ramazanoglu Partlak

Intellectual Property Specialist, Sanovel Ilac San.ve Tic. A.S., Turkey

Related Papers

March-In Rights at a Crossroad: What Biopharma Needs To Know Under Trump Administration
Few pieces of legislation have shaped the modern innovation landscape as profoundly as the Bayh-Dole Act of 1980. By allowing universities, small businesses, and non-profit organizations to retain ownership...Read more
Portrait image of Joanna Brougher
Joanna Brougher
Owner & Principal, BioPharma Law Group PLLC, USA
Portrait image of Bhavya Bhardwaj
Bhavya Bhardwaj
Student, University of Pennsylvania, USA
Patent Strategies for Attenuated Pathogen Vaccines
Malaria is a major health concern for people traveling to and living in malaria-endemic areas, causing 249 million clinical cases and 608,000 deaths in 2022, numbers essentially unchanged over the...Read more
Portrait image of David Dolberg
David Dolberg
Senior Director of Intellectual Property, Sanaria Inc., USA
Ways to Avoid Having your Patents Cellected*
The Court of Appeals for the Federal Circuit caused frustrations when it decided to affirm the U.S. Patent Office’s findings that claims in four patents were unpatentable because they are...Read more
Portrait image of Tom Irving
Tom Irving
Partner, Marbury Law Group, USA
Portrait image of Xiaoguang Michelle Gao
Xiaoguang Michelle Gao
Associate VP - Assistant General Patent Counsel, Eli Lilly and Company, USA
Portrait image of Michelle E. O'Brien
Michelle E. O'Brien
Partner, Marbury Law Group, USA
Section 112 Requirements for Life Sciences Patents
35 U.S.C. §112(a) of the US Patent Act is one of the integral parts of the quid pro quo patent system that balances the benefit of disclosure of the invention...Read more
Portrait image of Anagha Tendulkar
Anagha Tendulkar
In-house Patent Counsel, Cipla, India